Tesofensine_Dosage, benefits & legal status
Also known as NS2330
An experimental appetite-suppressing pill with strong weight-loss numbers.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is Tesofensine?
Plain language first. The technical label stays, but it never stands alone.Overview
It acts on the brain's appetite and reward system like a stimulant, to suppress hunger. That also means more risk to the heart.
Tesofensine is a small molecule, not a peptide, that blocks the reuptake of three brain chemicals: dopamine, noradrenaline, and serotonin.
What it's used for
An experimental appetite-suppressing pill with strong weight-loss numbers.
How does Tesofensine work?
What it does in the body, and where.Tesofensine is a stimulant-class small molecule, not a peptide. It was originally developed for Parkinson's disease, and the weight loss was noticed as a side effect.
- 01It blocks reuptake of dopamine, noradrenaline and serotoninKeeping all three circulating longer in the brain, which suppresses appetite.
- 02Appetite falls, and so does the reward from eatingThis works on the wanting rather than on fullness, which is a different mechanism from everything else in this category.
- 03Blood pressure and heart rate riseThe predictable cost of a triple reuptake inhibitor, and the reason its regulatory path has been difficult.
A schematic of the compound's mechanism, not a diagnostic image.
What else is it used for?
Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
- Appetite suppression and weight lossInvestigational
- Parkinson's and Alzheimer's disease, which is what it was originally developed for before those trials failedInvestigational
The published record
68
Records indexed for Tesofensine
51 in humans, 23 of them original studies.
14 registered trials, 5 with posted results.
Counted from Europe PMC indexing, not read by a person. Human means indexed under humans, which includes reviews and work on human cells. Original studies exclude reviews and lab work on human cells.Last updated 11 September 2026.
At a glance
Four things to know about Tesofensine
Evidence
Investigational
Category
Weight loss and metabolic
Common vial
Varies
Half-life
About 9 days
How much, and do you cycle it?
The range, and whether you take breaks.0.25 up to 0.5 mg per day, daily. Continuous daily dosing, studied to 24 weeksHuman study
Given daily without breaks in the trials. The phase 2 study ran 24 weeks at up to 1 mg daily, with an extension to 48 weeks. No cycling was used or tested.
Source: Astrup et al., TIPO-1: 24 weeks daily tesofensine (Lancet 2008;372:1906-13)
How long does it stay in the body?
The half-life, and where the figure comes from.About 9 daysTrial protocol
An active metabolite lasts far longer, around 16 days, so the compound keeps working well past the parent figure.
Source: Saniona clinical protocol NCT03488719. Bara-Jimenez W, et al. Mov Disord 2004;19(10):1183-6
You can compare this against the whole library to see where it sits.
What does it cost?
Typical dose and cost, in plain numbers.Tesofensine is not injected
It is taken by mouth (oral).
Tesofensine starts at $108.95 across 12 vendors.
14 listings, last read Sep 5, 2026. Shipping and card fees are not included.
How do you store it?
Before mixing, and after.Room temperature. Cool, dry, out of light.
Tesofensine is taken as a pill or capsule. Keep it in its original container at room temperature, away from heat, humidity, and direct sun. No fridge or mixing needed. Check the expiration date on the bottle.
What are the side effects and cautions?
Known cautions and warnings for this compound.Who should avoid it
- Uncontrolled high blood pressure
- Heart rhythm problems
- A history of psychiatric conditions
- Pregnancy
Stop and get help
- A racing or pounding heartbeat
- Severe agitation, panic, or a marked change in mood
- Chest discomfort
- Signs of an allergic reaction such as face or throat swelling, hives, or trouble breathing
Common effects
- Dry mouth and difficulty sleeping
- Constipation, diarrhea, and nausea
- A rise in blood pressure and heart rate, which is the main safety concern
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is Tesofensine approved?
And where the numbers on this page come from.No. Tesofensine is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteBy mouth (oral)
- CheckedSeptember 2026
What has happened recently
We have not yet written a full regulatory note for this compound. The status above is current as of the date shown.
You can compare this against the whole library, or read how to check a seller.
- DoseFrom published clinical trials. Not approved by a regulator for this dose.
- Vial sizeFrom what vendors typically list; not a recommendation.
- SourcesClinicalTrials.gov NCT00394667, effect of tesofensine on weight reduction in patients with obesityAstrup et al., effect of tesofensine on bodyweight loss, body composition and quality of life in obese patients, LancetAstrup et al., Under-reporting of adverse effects of tesofensine (The Lancet, correspondence)
- Reviewed8 September 2026
What else is like Tesofensine?
Others in Taken without a needle, side by side.If you're weighing Tesofensine, it's worth reading Danuglipron, MK-677 (Ibutamoren), and VIP (Vasoactive Intestinal Peptide) in the same class.
An experimental appetite-suppressing pill with strong weight-loss numbers.
- Dose
- 0.25 up to 0.5 mg per day
- How often
- Daily
An experimental weight-loss pill whose development was stopped over a liver-injury signal.
- Dose
- 40 up to 200 mg per dose
- How often
- Daily
A once-daily pill that raises growth hormone for sleep, appetite, and muscle.
- Dose
- 10 up to 25 mg per day
- How often
- Daily, at night
A nasal-spray peptide used to calm chronic inflammation and immune problems.
- Dose
- 0.05 mg per dose
- How often
- Several daily
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
- Semaglutide vs Tirzepatide vs Retatrutide
One receptor, two, or three. Mechanism, trial weight loss, side effects, and real cost.
Sources
- ClinicalTrials.gov NCT00394667, effect of tesofensine on weight reduction in patients with obesity(2008)The registry entry for the landmark phase 2 trial lists, among its references, an Expression of Concern published in the Lancet in 2013 (PMID 23561987) about that same trial. Anyone citing the 2008 result should know the journal later flagged it.
- Astrup et al., effect of tesofensine on bodyweight loss, body composition and quality of life in obese patients, Lancet(2008)Summary of the phase 2 result. At 0.5 mg, mean weight reduction was 9.2 percent above placebo, and 87 percent of participants lost 5 kg or more against 29 percent on placebo. Dose-dependent rises in diastolic blood pressure and heart rate were also reported.
- Astrup et al., Under-reporting of adverse effects of tesofensine (The Lancet, correspondence)(2013)Every page selling this compound quotes the 2008 Lancet trial. This is what the authors of that trial wrote five years later, after The Lancet published an Expression of Concern against it. A Danish Health and Medicines Authority audit of two of the five sites found that investigators had been wrongly instructed by the trial monitors not to record headache, migraine, stress or depression as adverse events in patients who had reported those conditions before randomisation. The authors are defending their work here, and they still state plainly that the listed adverse events from all centres were under-reported in the published paper. They also quote the audit's conclusion about the table of adverse events that caused participants to leave the trial: it does not appear in the clinical report and rests on data collected without adequate scientific control or quality control. The efficacy figures were never retracted, and the Expression of Concern has never been resolved. The corresponding author discloses honoraria as a member of the tesofensine advisory board and consultancy for the company that was developing it.
Last reviewed 8 September 2026
Beyond these, 68 records are indexed. Browse the records